15714563falseConsultancy2025-06-012026-05-31http://www.companieshouse.gov.uk/2025-05-31http://www.companieshouse.gov.uk/cd:CompanySecretary12025-06-012026-05-31http://www.companieshouse.gov.uk/pt:ShareCapital2025-05-31http://www.companieshouse.gov.uk/cd:Director12025-06-012026-05-31http://www.companieshouse.gov.uk/pt:ShareCapital2026-05-31http://www.companieshouse.gov.uk/pt:ToolsEquipment2025-05-31http://www.companieshouse.gov.uk/cd:OrdinaryShareClass12025-06-012026-05-31http://www.companieshouse.gov.uk/pt:ToolsEquipment2026-05-31http://www.companieshouse.gov.uk/cd:RegisteredOffice2025-06-012026-05-31http://www.companieshouse.gov.uk/cd:AuditExemptWithAccountantsReport2025-06-012026-05-31http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments2026-05-31http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments2025-05-31http://www.companieshouse.gov.uk/2025-06-012026-05-31http://www.companieshouse.gov.uk/2025-05-31http://www.companieshouse.gov.uk/cd:FRS1022025-06-012026-05-31http://www.companieshouse.gov.uk/2026-05-31http://www.companieshouse.gov.uk/cd:PrivateLimitedCompanyLtd2025-06-012026-05-31http://www.companieshouse.gov.uk/cd:FilletedAccounts2025-06-012026-05-31iso4217:GBPxbrli:sharesxbrli:pure
Registered number: 15714563

Pharma4orce Ltd

ACCOUNTS
FOR THE YEAR ENDED 31/05/2026

Prepared By:
Anstee Gorst
Unit 4 Eaton Court
Colmworth Business Park
Eaton Socon
Cambridgeshire
PE19 8ER

Pharma4orce Ltd

ACCOUNTS
FOR THE YEAR ENDED 31/05/2026
DIRECTORS
Richard Bell
SECRETARY
Barbara Bell
REGISTERED OFFICE
The Village Farmhouse
6 Village Road, Cockayne Hatley
Sandy
Bedfordshire
SG19 2EE
COMPANY DETAILS
Private company limited by shares registered in EW - England and Wales, registered number 15714563
ACCOUNTANTS
Anstee Gorst
Unit 4 Eaton Court
Colmworth Business Park
Eaton Socon
Cambridgeshire
PE19 8ER

Pharma4orce Ltd

ACCOUNTS
FOR THEYEARENDED31/05/2026
CONTENTS
Page
Directors' Report-
Accountants' Report-
Statement Of Comprehensive Income-
Balance Sheet3
Notes To The Accounts4
The following do not form part of the statutory financial statements:
Trading And Profit And Loss Account-
Profit And Loss Account Summaries-

Pharma4orce Ltd

BALANCE SHEET AT 31/05/2026
20262025
Notes££
FIXED ASSETS
Tangible assets31,1561,541
CURRENT ASSETS
Stock-3,525
Debtors52,732487
Cash at bank and in hand92,86474,756
95,59678,768
CREDITORS: Amounts falling due within one year624,90037,115
NET CURRENT ASSETS70,69641,653
TOTAL ASSETS LESS CURRENT LIABILITIES71,85243,194
PROVISIONS FOR LIABILITIES AND CHARGES7289385
NET ASSETS71,56342,809
CAPITAL AND RESERVES
Called up share capital8100100
Profit and loss account71,46342,709
SHAREHOLDERS' FUNDS71,56342,809
For the year ending 31/05/2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have decided not to deliver to the registrar a copy of the company's profit and loss account.
Approved by the board on 24/09/2026 and signed on their behalf by
.............................
Richard Bell
Director

Pharma4orce Ltd

NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31/05/2026
1. ACCOUNTING POLICIES
1a. Basis Of Accounting
The accounts have been prepared under the historical cost convention.
The accounts have been prepared in accordance with FRS102 section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006 .
1b. Depreciation
Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives.
Equipmentreducing balance 25%
1c. Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell (net realisable value). Costs, which comprise direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs.
When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of stocks to net realisable value and all losses of stocks are recognised as an expense in the period in which the write-down or loss occurs. The amount of any reversal of any write-down of stocks is recognised as a reduction in the amount of stocks recognised as an expense in the period in which the reversal occurs.
2. EMPLOYEES
20262025
No.No.
Average number of employees1-

Pharma4orce Ltd

3. TANGIBLE FIXED ASSETS
EquipmentTotal
££
Cost
At 01/06/20251,6361,636
At 31/05/20261,6361,636
Depreciation
At 01/06/20259595
For the year385385
At 31/05/2026480480
Net Book Amounts
At 31/05/20261,1561,156
At 31/05/20251,5411,541
4. STOCK 20262025
££
Stock comprises:
Work in progress-3,525
-3,525
5. DEBTORS 20262025
££
Amounts falling due within one year
Trade debtors1,980-
PAYE control115-
Other debtors4-
Prepayments633487
2,732487

Pharma4orce Ltd

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
20262025
££
UK corporation tax16,52918,619
VAT5,61016,167
Directors current account1,4722,329
Trade creditors204-
Accruals1,085-
24,90037,115
7. PROVISIONS FOR LIABILITIES 20262025
££
Deferred taxation289385
289385
8. SHARE CAPITAL 20262025
££
Allotted, issued and fully paid:
100 Ordinary of £1 each100100
100100